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Emergency contraception is a common practice now. Many categories of 
drugs are marketed  with modifications in dosage, in combination and even in 
the timing of  administration. Recent re-analysis suggests that there is still no 
uniformity of opinion on the actual mechanism of action and this has often 
fueled the ethical controversy. This review  analyzes the most common 
emergency contraception drugs:  levonorgestrel, mifepristone and  ulipristal 
acetate about their action underlining  that the hormonal products, when used 
in emergency contraception, play different roles depending on the phase of the 
menstrual cycle during which they are administered.This review aims to 
examine rigorously  the most accredited literature to verify if a evidence-
based uniformity of opinions has been achieved about the biological effects of 




Key words: emergency contraception, levonorgestrel, mifepristone, ulipristal acetate.
Translational Medicine @ UniSa, - ISSN 2239-9747 2011, 1(1): 271-294 
 
272 





Since the second half of the last century, hormonal products have began to be used for 
contraceptive purposes as a social consequence of a real “cultural revolution” [1]. 
The role of the hormonal contraception has been crucial to foster women's empowerment and 
gender equality [2,3]. 
Moreover, unlike other categories of drugs, the contraceptive products (generally referred to 
as “the pill”) have undergone continuous modifications in dosage, combination and even in 
the timing of drug administration – today it is administered also after sexual intercourses 
[4,5]. Nowadays we can state that hormonal contraception can be prescribed to healthy 
women of all ages [6]. 
Nevertheless, these progresses have initially met harsh resistances from the doctors 
themselves mainly for ethical and religious reasons especially when cases may occur that 
hormonal products would damage embryo and not only avoid conception. 
This is still a highly topical issue especially when considering the so-called “emergency 
contraception” that makes use of hormonal products only after a sexual intercourse. 
Scientific literature and international cultural debate have not yet reached a common view on 
the actual mechanism of action of some hormone molecules when administered after sexual 
intercourse. It is clear that the ethical (and thus religious) judgement cannot neglect the strict 
and rigorous awareness of the effects that the hormonal emergency contraception causes 
before and after conception, that is damage to the embryo or before the embryo starts to 
develop. 
Bitter controversy have aroused about this delicate issue. This review wants to underline that 
very often there is no clear distinction between the legal aspects and the ethical aspects of this 
issue. 
On the contrary, we deem that the legal aspect of the use of emergency contraception should 
be appraised according to the law in force in each country.   
Ethical facets do not take into consideration the legal frameworks, indeed they need a moral 
evaluation. In short, it only answers the question about the possible damage that these 
hormones may cause on the embryo which a lot of religions consider untouchable. 
It goes without saying that those who are in favour of intentional abortion (usually included 
in the legislation of many countries) will see no harm in emergency contraception taking 
place at the very early phases of the embryo development and will consider this opportunity 
as an improvement in the health services offered to the women who do not intend to carry on 
an unexpected pregnancy. 
It is nonetheless true that those who do administer hormones to avoid conception (generally  
referred to as “contraception”) might not administer hormones after conception (generally 






Over eighty years have passed since the first attempts to develop a method that interferes 
with the events subsequent to sexual intercourse.  
Since 1920 it's known that estrogen -when administered early- could interfere with 
pregnancy; the first case reported in the 1960s literature is about a raped girl in a presumably 
ovulatory period, who was submitted to estrogen administration [7]. Since then, an increasing 
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number of women was treated with high doses of conjugated estrogens, until -in the early 
70s- the combined administration of estrogen and progestin was proposed.  
In 1972, Yuzpe, a Canadian researcher published the first experimental data, using the self-
called method [8]; meanwhile, trials with only made progestin drugs began [9], and in the late 
70s the intrauterine device between the forms of “emergency contraception” [10] was 





Even the definition itself has aroused a lot of controversies about the use of emergency 
contraception. There are at least two main schools of thought: those who believe abortion 
only occurs after embryo have implanted into the uterus (they state that the hormones 
administered before implantation can be considered “contraception”) and those who believe 
that also the interruption of the embryonic development, before implantation, represents an 
abortion (they claim that the hormones administered after the conception are “abortion”). 
It's very important to define the beginning of pregnancy; on one side, the principal scientific 
associations believe that it begins with the egg’s implantation [12-16]; in the early 70s the 
ACOG (American College of Obstetricians and Gynecologists) has redefined the concept of 
pregnancy; the term “pregnancy “ refers to the period between the implantation of the embryo 
in the uterus and childbirth [17]. On the other side, other authors believe that pregnancy starts 
when oocity is fertilized, assuming that the embryo is “born” in that stage [18,19]. 
To better understand the difficulties rising from the definition of “contraception” we must 
remember that in humans (assuming an average duration of the menstrual cycle of 28 days) 
the normal length of pregnancy is 40 weeks, totaling 280 days, calculated from the starting 
day of the last menstrual period. Instead, considering the  ovulation day, the normal duration 
of  the conception’s product development  is 38 weeks, equal to 266 days. In this case, 
therefore, the term  “pregnancy” includes not only the period from fertilization to birth, but 
also the 15 days preceding ovulation, since the reference empirically detectable is the last 
menstrual period [20]. 
Considering these dissimilar points of  view, a differentiation have to be made between  the 
concept of “emergency contraception”, “interception” and “abortion”. 
Emergency Contraception -according to the WHO and the ACOG- is defined as all these 
methods that can give to the women a no risky way to prevent an unwanted pregnancy after 
unprotected intercourse, or in case of contraceptive failure, when it is used within 120 hours 
from unprotected intercourse [16,21].  
Instead, if we consider begin of the pregnancy when the egg is fertilized, the use of post-
coital methods may fall under the definition of abortion [18,19] 
Even as regards the definitions of abortion, there are different points of view. 
The definition suggested by WHO considers as abortion both the pregnancy terminated 
within 20 weeks of gestation and a born weighting less than 500g fetus; in other words, the 
process of gestation is included between the period when the zygote attaches itself to the 
uterine wall (about 14 days after conception), and the time when the fetus is  capable of 
surviving on its own [21,22,23]. 
Others consider abortion as any method that acts by interrupting the pregnancy from the 
moment the egg is fertilized [24,25,26]. 
Interception is different from abortion because of the moment in which the contraceptive 
methods can interfere with the blastocyst implanting in the uterus [27,28,29]. 
 Following some authors , the term  “interception” corresponds to the term  “abortion” [30].  
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As a general rule “emergency contraception” can be achieved using the drugs reported in the 
following table [Tab1].This reviews aims at studying the most recent drugs around which the 
controversy about the actual mechanism of action has developed. 
 
 
2- Levonorgestrel (LNG) 
 





Levonorgestrel is a second generation synthetic progestogen used as an active ingredient in 
some hormonal contraceptives; chemically, it is a hormonally active levorotatory enantiomer 
of the racemic mixture norgestrel. It is a progestin derived from 19-nortestosterone [31]. 
LNG represents the active isomer of norgestrel and is administered orally or delivered either 
via an intrauterine device or from subdermal implants  [32]. 
The levonorgestrel-only pill is commonly used for emergency contraception (EC), a back-up 
method for contraceptive failure which a woman can use within a few days of an unprotected 
intercourse to prevent an unwanted pregnancy.  
The standard regimen is to be administered within 72 h (can be extended to 120 h) of an 
unprotected intercourse, 1.5 mg either as a single dose or in two doses 12 h apart [33]. This 
regimen is estimated to reduce a woman’s risk of becoming pregnant by 57–93% [34- 38]. 
As EC the levonorgestrel intrauterine system and cupper intrauterine device [39] can be 
inserted up to five days after unprotected intercourse. 
The levonorgestrel intrauterine system presents a lower incidence of pelvic inflammation and 
irregular bleeding. 
A disadvantage of this type of contraception is that it can't be used  in women with vaginal 
infections, sexual infections and pelvic inflammatory disease. 
 
 
2.2 Mechanism of action 
 
 
There is wide controversy about the possible mechanism throughout the LNG, used for 
emergency oral contraception, prevents pregnancy; this is still an open question [40- 44] . 
We considered both Levonorgestrel impact on ovulation and on endometrium. 
 
 
2.2.1 Impact on ovulation 
 
 
Hapanagama et al. [45] studied twelve healthy women with regular cycles. 
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They administed LNG in the fertil period that was identifyed considering changes in the 
hormones levels of oestrone - 3 - glucuronide (E3G), a urinary metabolite of oestradiol and 
LH, evaluated with a monitoring system that includes disposable test sticks and a hand-held 
monitor. 
Six women received LNG in the first study cycle and placebo in the third study cycle;  the 
remaining six women received placebo in the first study cycle and LNG in the third study 
cycle. 
The second study cycle was a washout phase for all women during which they also received 
placebo. 
Seven women had apparently normal ovulatory cycles after taking LNG; five of them took 
LNG on the day before the LH surge and one on the day of the surge. In the four women in 
whom the LH peak and ovulation was delayed, the LNG was taken within three days of the 
predicted LH peak; one woman did not ovulate at all despite having an LH surge two days 
after taking LNG. 
This seven women, who apparently ovulated normally, had a reduced total luteal LH and a 
shortened luteal phase; in fact, basal levels of LH are essential for the normal secretory 
function of the corpus luteum. 
This study suggests that LNG -taken immediately before ovulation- acts as an emergency 
contraceptive by delaying or preventing ovulation. 
Durand at al. [46] studied fourty-five healthy women with regular menstrual cycles. 
All participants were admitted during the first ten days of their menstrual cycle and after a 
control cycle, were randomly allocated into four different groups: Group A: 15 women 
received two doses of 0,75 mg LNG taken 12 hours apart, with the first dose given on the 
morning of day ten of the menstrual cycle; Group B: 11 women received the same dose of 
LNG immediately after positive LH detection in urine; Group C: 11 women received the 
same dose of LNG 48 hours after positive detection of  urinary LH and Group D: 8 women 
received the same dose of LNG in the late of follicular phase LH- (3 +/- 1). 
Transvaginal ultrasound and serum LH were performed daily since the detection of urinary 
LH until follicular rupture. In addition, endometrial biopsies were taken – from all 
participants- at the day 9 after the LH peak. 
Twelve participants of Group A did not ovulate and three did not ovulate but presented a 
significantly shorter luteal phase with lover progesterone levels. 
In Groups B, C and D no modifications were noted in follicular phase length between 
treatment and control cycle. 
In Groups B and C, no significant differences on either cycle length or luteal progesterone 
and estradiol concentrations were observed, while in Group D the cycle length was normal 
but progesterone luteal levels were significantly lower. 
As to endometrial histology, the author concluded that in both control and treated cycles, 
weren't observed inflammatory reactions or other abnormal features. 
Only twenty-four of the thirty-three biopsies were studied, because of insufficient tissue 
sample. 
Marions et al. [47] studied twelve administered LNG-ECPs (0,75 mg twice, 12 h apart) to six 
women twice: the first time two days before ovulation; the second time two days after 
ovulation. 
They evaluated both the urinary hormonal levels and on endometrial biopsy obtained six-
seven days after LH surge. 
LNG pre-ovulatory treatment inhibited the LH peak; the post-ovulatory treatment did not 
affect the cycle pattern, but the endometrium was normal only in three patients, out of phase 
in two and insufficient in one. 
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Subsequently Marions [48] administered the same treatment to seven women two days prior 
to ovulation (day -2; assessed by ultrasound). 
Both the urinary hormones and the destiny of the leading-follicle were evaluated. The 
treatment caused either a delay or an inhibition of the LH peak in all subjects. 
A significant delay in P4 levels and an initial suppression of E1 levels were also noted. 
The development of the leading follicle was either arrested or continued without signs of 
rupture. 
This study indicates that, when used for EC, LNG administered prior to ovulation acts 
through an impaired ovulatory process and luteal function. 
Croxatto et al. [49] studied fifty-eight patients presumed healthy and normally cycling and 
valuated the effects of the standard LNG regime (0,75 mg X 2, with a 12 hours interval 
between doses) or a single dose (1,50 mg) or placebo.  
Participants were randomly assigned to three groups: one group received the first pill when 
the leading follicle reached a mean diameter of 12-14 mm (n=18); in the second group, it was 
given when the diameter of the follicle was 15-17 mm (n=22), the third group received the 
first pill when the follicle reached  18 mm. 
As result, the spontaneous occurrence of either lack of follicular rupture or ovulatory 
dysfunction was rather high: up to 62% when given LNG-ECPs at a follicle diameter of 12-
14 mm, 45% at 15-17 mm and 13% when the follicle diameter  already reached > 18 mm. 
Subsequently, Croxatto with Noè et al. [50] conclude that LNG-EC prevents pregnancy only 
when taken before fertilization of the ovum has occurred; they studied a cohort of women 
attending a family planning clinic for EC. 
On the day of intake of LNG-EC and during five days follow-up, blood samples were taken 
for examination of luteinizing hormone, estradiol and progesterone concentrations, and 
vaginal ultrasound examinations were done for size of the leading follicle and/or corpus 
luteum. Of 388 women attending for LNG-EC, 122 women had intercourse on fertile cycle 
days according to ultrasound and endocrine findings.  
At the time of LNG-EC intake, 87 women were in Days -5 to -1 and 35 women were in Day 
0 (day of ovulation) or beyond. With the use of the probability of clinical pregnancy reported 
by Wilcox et al. [N Engl J Med 333 (1995) 1517-1521], expected numbers of pregnancies 
among the 87 and 35 women were 13 and 7, respectively, while 0 and 6 pregnancies, 
respectively, occurred. 
Recently the International Consortium for Emergency Contraception (ICEC) in collaboration 
with the International Federation of Gynecologists  and Obstetrics (FIGO) has updated its 
joint Statement “How do LNG-only emergency contraceptive pills (LNG ECPs) work to 
prevent pregnancy?”. 
The statement concludes that inhibition or delay of ovulation is LNG ECPs principal and 
possibly only mechanism of action; they still added that ''Review of the evidence suggests 
that LNG ECPs cannot prevent implantation of fertilized egg [51,52]. 
The Statement conclusion isn't shared by other authors [44]. 
Mozzanega take in consideration and analyze the works [45-49] on which is based the 
Statement and he observe that only Marion's series [47,48] supports the Statement directly; in 
all the others the evidences are strikingly contrasting. 
In the patients in which LNG really delayed or inhibited ovulation [45,46] were at the 
beginning of their fertile period when they received ECPs and so were the patients [49] 
treated when the leading-follicle had a mean diameter of 12-14 mm; unprotected sex in any 
previous day did likely occur when they were still infertile and the risk of pregnancy was 
likely null. 
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At last, he conclude that the number of the patients is really small and that the sample is not 
representative. 
 
2.2.2 Impact on endometrium 
 
 
As regard the LNG impact on endometrium, the attenction of scientific literature is direct to 
investigate the LNG effects on the glycodelina endometrial expression and on glycodelina 
serum concentrations, both during peri-ovulatory midcycle [53,54] and at the time of LH 
surge [53,55]. 
Glycodelin is the mayor progesterone-regulated glycoprotein that is secreted into uterine 
luminal cavity by secretory/ decidualized endometrial glands [56]. 
Absence of glycodelin in the uterus during periovulatory midcycle is consistent with an open 
“fertile window”. 
So, human endometrium contains no detectable glycodelin during the peri-ovulatory 
midcycle; the first appearence of glycodelin in endometrium is observed three days after the 
LH surge and its significant increase five-six days after LH surge, at the opening of the 
implantation window [57]. 
Glycodelin inibits NK cell activity [58], monocytic cell chemotaxis [59], T-cell proliferation 
[60], and it induces T cell apoptosis [61] at the concentrations present in endometrial tissue 
and uterine fluid.  
Glycodelin induced by  local or systemic administration of progestogens may potentially 
reduce the fertilizing capacity of sperm in any phase of the menstrual cycle: it is the first 
endogenous glycoprotein that was found to potentially and dose-dependently inhibit binding 
of human sperm to the sona pellucida [62]. 
Durand et al. [53] examined serum glycodelin concentrations and endometrial expression 
during the luteal phase following oral administration of levonorgestrel (LNG) at different 
stages of the ovarian cycle.  
She studied thirty women that were allocated into three Groups; Group 1 received LNG on 
days 3-4 before the LH surge, Group 2 received LNG at the time of LH rise and Group 3 
received LNG 48 h after the LH surge. 
Serum progesterone and glycodelin were measured daily during the luteal phase. 
The treatment with LNG before the LH surge shortened by four days the lag period before 
appearance of glycodelin in serum during the luteal phase. Serum glycodelin levels steadily 
rose from day LH+ 2 to days LH+7-8 after which they declined. 
In this way the hormonal EC with LNG, taken before the LH surge, alters endometrial 
glycodelin secretion in two important phases of the cycle: the first is in the fertile window 
during which an early increase of glycodelin secretion is interest for its antifertility activity; 
the second is in the phase of uterine receptivity in which reduced glycodelin expression may 
reflect weakened immunosuppressive microenvironment within the uterus at the time of 
implantation.  
Subsequently Durand [54] studied thirty healthy sterilized women with normal ovarian 
function; each woman received LNG during the pre-ovulatory phase approximately two days 
before the LH surge. 
Both LNG did not modify follicle rupture in 20 of 30 women and serum glycodelin 
concentrations significantly increased during the early and mid-luteal phases. 
These results may represent an additional action of LNG in situation where the intervention 
did not interfere with ovulation. 
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Durand [53] and Palomino [55] studied the effects of LNG when its was administered on the 
day of  LH surge without changes of the secretory pattern of glycodelin in serum in the luteal 
phase. 
Last, but not last, Meng et al.[63] studied a considerable number of markers of endometrial 
receptivity in women after LNG oral or vaginal administration. 













In 1980, Etienne-Emile Baulieu, working for the laboratories of Roussel Uclaf on 
progesterone derivatives discovered a potent anti-progestin, initially called RU-38486 
(abbreviated in RU486)  Mifepristone:  is a steroid with affinity for the progesterone and 
glucocorticoid receptors, greater than that of natural compounds [64].  
There are several uses of mifepristone. Administration of RU486 followed by the 
prostaglandin, misoprostol, has been used successfully in the medical termination of 
pregnancy.This is the best known application of this drug. However  doses of Mifepristone 
are also effective as contraceptive [64]. Also single doses of the drug appear to be effective as 
emergency contraception [64-66], but it is only market in China [49,67, Tab1]. 
 
 
3.2 Mechanism of action 
 
 
The effect of Mifepristone is on progesteron receptor. These belongs to a family of nuclear 
receptors includes receptors for the steroid hormones (glucocorticoid, mineralocorticoid, 
androgen, estrogen, and vitamin D) as well as for thyroid hormones and retinoids. These 
receptors are ligand-activated transcription factors with domains for DNA binding, hormone 
binding, and transactivation [68]. 
Specifically PR type A and B even if have similar DNA binding activities, they have different 
functional activities which depend on the cell type [65,69]. Studies carried out in PR-A and 
PR-B knockout mice have shown that PR-A is important for fertility, ovulation and uterine 
receptivity and mediates the anti- proliferative effect of progesterone in the follicular 
endometrium  phase; Instead PR-B mediates differentiation and development of the 
mammary gland [70]. 
In the presence of mifepristone, receptors adopt an inactive conformation recruits 
corepressors such as nuclear receptor corepressor and silencing mediator of retinoic acid and 
thyroid hormone receptor. The result is a loss of transcriptional activity [71]. 
The action of Mifepristone in terminating early pregnancy, combinating with misoprostol, is 
due to its effects on the glucocorticoid [72] and progesterone [64] receptors located in the 
uterus. Both misoprostol and mifepristone induce cervical dilatation. Glucocorticoid receptor 
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blockade may result in an inappropriate cytokine response of the immune system [73].The 
dose to achieve abortion is 200mg [74]. 
The contraceptive use of  Mifepristone is due to its uterine and ovarian effects [75-77]. 
Instead emergency post-coital contraception  probably is primarily due to inhibition of 
ovulation rather than inhibition of implantation [78]. 
It’s important to remark that the effects of  Mifepristone vary depending on when the drugs is 
administer and the dose given.  
 
 
3.2.1 Impact on ovulation 
 
 
Administration of  Mifepristone during the follicular phase  of the menstrual cycle delays the 
estrogen rise and the luteinizing hormone (LH) surge. Specifically the treatment with 10mg  
prior to ovulation showed more a tendency to postpone ovulation [78]. 
The precise mechanism by which mifepristone affects the timing of ovulation is enigmatic. 
Infact Mifepristone has been shown not to alter the pattern of pulsatile secretion of LH 
[79,80] or pituitary responsiveness to gonadotrophin-releasing hormone (GnRH) [81].  
The ability of mifepristone to perturb ovulation and FSH secretion is thought to be a result of 
the anti-progestogenic effect [78], even if seems that mifepristone significantly modified 
circulating levels of leptin.  Evidences suggest that leptin is an important modulator of the 
timing of menstrual cycles. Infact in laboratory animals, leptin is known to regulate GnRH 
secretion via neuropeptide Y [82], and prevents suppression of gonadotrophin secretion [83]. 
In humans, leptin can regulate the nocturnal LH profile in the mid- to late follicular phase 
that precedes ovulation [84].  
The adipocytes expression and release of leptin from adipose tissue is stimulated by 
glucocorticoids [85-87]. So Mifepristone, with is anti-glucocorticoid action, suppress leptin 
in fat. It was also demonstrated with cultured adipocytes [88].  There is the possibility that, in 
humans, suppression of circulating leptin concentrations following ingestion of mifepristone 
(10 mg) contributes to the subsequent and transient decrease in gonadotrophin secretion [76]. 
 
 
3.2.2 Impact on Endometrium 
 
 
When a sufficient dose of mifepristone (10,50,600 mg) is given immediately after ovulation 
will significantly inhibit endometrial development [89,90]. It will also inhibit the expression 
of endometrial markers of endometrial receptivity such as  leukema inhibitory factor, 
integrins, and cyclooxygenase [91,92]. 
Particularly, a single dose administation of mifepristone produces several effects in the 
endometrium, myometrium and decidua. If implantation has occurred, the inhibition of 
transcription by the mifepristone-PR complex results in down-regulation of progesterone-
dependent genes with decidual necrosis and detachment of products of conception [93]. It 
also directly promotes uterine contractions by increasing myometrial cell excitability, 
establishing gap junctions between cells and influx of calcium [94]. It also increases the 
release of prostaglandins by decidual cells [95]. 
Mifepristone may also affect tubal functions at high dose (200mg) after LH surge. The tubal 
microenvironment is of great importance; Infact the preimplanting embryo is exposed to a 
changing, hormonally regulated during its time in the tubal lumen. It is likely that in the 
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Falloppian tube the secretion of local factors, such as cytokines, is regulated by steroidal 
hormones; The inhibition of progesteron receptor mediated by mifepristone may impair the 
normal secretion of these cytokines [96].  
Furthermore progesterone regulates tubal transport in vitro [97]; so a too rapid or too slow 
tubal transport could also be expected to cause desynchronization between the embryo and 
the tube, or the blastocyst and the endometrium [98,99]. Infact animal studies have previously 
shown accelerated tubal egg transport after mifepristone treatment [99].  
Even if it is sure that in human,  progesterone receptor concentration increased in tubal cells 
after Mifepristone administration, nevertheless the mechanism of action of these regimens 
when used for emergency contraception is not fully explained [96,98]. 
So Mifepristone can be used as emergency contraceptive as abortive/interception drug 










Some trials show an higher failure rates when levonorgestrel is taken 48 hours or more after 
unprotected intercourse [37,100] so in May 2009 , ulipristal acetate(UPA) was approved by 
EMEA as a safe and effective method of emergency contraception for use up to 5 days after 
unprotected sexual intercourse, on the basis of different trials [101-104] that included more than 
4000 women. 
UPA is a selective progesterone receptor modulator that inhibits or delays ovulation in 
women presenting 48-120 hours after unprotected intercourse when levonorgestrel efficacy 
markedly wanes. UPA has been shown to prevent ovulation and then fertilization even after 
the luteinizing hormone surge has begun [105]. 
UPA is orally active and taken as a single dose. So UPA is well accepted by women despite 
the insertion of an intrauterine device that many women find it unacceptable [106]. The major 
of women experience normal menses within 7 days of the expected date.  Glasier [101] 
studied 1696 women. They received emergency contraception within 72 hours of sexual 
intercourse (UPA, n=844; levonorgestrel, n=852). 
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There were 15 pregnancies in the UPA group and 22 in  the levonorgestrel group. In 203 
women who received emergency contraception between 72 hours and 120 hours after sexual 
intercourse, there were three pregnancies, all in the levonorgestrel group. 
This trial shows that UPA is non inferior to levonorgestrel for emergency contraception. This 
finding accords with the results of an earlier trial in which ulipristal acetate was at least as 
affective as levonorgestrel when taken up to 72 hours after sexual intercourse [102]. 
For women who present on the fourth or fifth day after sexual intercourse, UPA provides 
significant prevention of pregnancy whereas levonorgestrel did not and so for use beyond 72 
hours and up 120 hours [101]. 
 
3.2 Mechanism of action 
 
UPA exerts its pharmacological activity by binding  progesterone receptors to produce an 
anti-progesterone contraceptive effect on ovary and on endometrium (endometrial thickness). 
These effects vary according to the timing of drug administration during the menstrual cycle 
[107]. 
In addition to its effect, UPA binds to glucocorticoid and androgen-receptor. However, its 
capacity as an antagonist in binding to these receptors is markedly lower than its anti- 
progestational activity [108]. 
 
3.2.1 Impact on ovulation 
 
The first studies to understand how the progesterone plays a key role during ovulation were 
done on mice.  Mice lacking progesterone receptor gene fail to ovulate due to a defect in 
follicular rupture [108,109]. 
The biological effects of UPA vary according to the time of menstrual cycle that the drug is 
given and the doses. Singles doses of UPA administered during the mid-follicular phase 
suppress leading follicle growth, causing a dose-dependent delay in folliculogenesis. At 
higher doses, a new leading follicle is often recruited [110]. 
The effect of UPA at different follicular diameters and in relation to the LH peak and 
ovulation was studied. When given prior to LH rise, UPA inhibited 100% of follicular 
ruptures. When the size of the leading follicle was at least 18mm, follicular rupture failed to 
occur within the 5 and 6 days following UPA treatment in 20 (59%) and 15 (44%) subjects 
respectively. Even on the day of the LH peak UPA could delay ovulation for 24 to 48 hours 
after administration. Taken together these studies demonstrate that UPA may have a direct 
inhibitory effect on follicular rupture. This allows UPA to be effective even when 
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administered immediately before ovulation when LH has already started to rise, a time when 
use of LNG or Yuzpe is too late for ovulation inhibition [105]. 
Other authors studied pathways that modulate ovulation: gene expression profiling was 
performed using ovaries from mice subjected to gonadotropin induced superovulation in the 
presence and in the absence of UPA. Prominent among  the genes that were down-regulated 
in response to UPA was endothelin-2, a potent vasoactive molecule.  Endoteline-2 mRNA 
was transiently induced in mural granulosa cells of the preovulatory follicles immediately 
preceding ovulation. Furthermore, mice trated with an endothelin selective antagonists of 
endothelin receptor B exhibited a dramatic (> 85%) decline in the number of released oocytes 
[111]. 
Administering UPA before ovulation causes delayed follicle development and release, 
probably a result of suppression of estradiol levels. If the EC drug is taken during the LH 
peak, follicular rupture and ovum release may also be delayed [108]. 
3.2.2 Impact on endometrium 
 
During the latter part of the menstrual cycle, UPA’s affect may be attributed to its ability to 
decrease endometrial thickness [112]. 
UPA, given at high or repeated doses have an effect on endometrial histology that could 
theoretically impair implantation of a fertilized oocyte [113].  
Glasier believes that the dose of 30 mg of ulipristal acetate [101] was specifically titrated for 
emergency contraception on the basis of inhibition of ovulation and might be too low to 
inhibit implantation. 
Fifty-six women with regular cycles were studied by  Stratton et al. [113], using  a single 
dose of UPA (10,50 or 100 mg) or placebo  after ovulation and within 2 days of the LH 
surge. Four to six days later, a transvaginal ultrasound scan measured endometrial thickness, 
and an endometrial biopsy specimen was obtained. The endometrium was evaluated by 
immunohistochemical analysis for progesterone (P) –dependent markers.  
UPA caused a significant dose-dependent decrease in endometrial thickness, an increase in 
glandular P receptors, and a decrease in peripheral node addressins. Estradiol and P levels 
and menstrual cycle timing were not altered. 
The endometrial development was considered abnormal if there was > 2 days delay of 
pathologic dating compared with the chronologic day of cycle. The chronologic day of cycle 
was determined as the number of days from ultrasound-documented ovulation to biopsy.  
Similar endometrial effects have been observed among those receiving mifepristone 
[114,115]. 
UPA also was associated with decreased expression of peripheral node addressins, which are 
important L-selectin ligands found on the surface of endothelial cells. Recent studies have 
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shown that L-selectin ligands are up- regulated during the implantation window, making the 
uterus more receptive to the trophoblast [116,117]. 
All these evidences would interfere with the implantation phase. 
 
4-Discussions and conclusions 
 
This review demonstrates that the hormonal products used in emergency contraception play 
different roles depending on the phase of the cycle during which they are administered. As 
things stand now, this conclusion allows to consider that in some cases the effect falls under 
hormonal contraception before the formation of the embryo and in some other cases the effect 
falls under the interruption of the development of an already formed embryo. Statistically, it 
is not possible to determine which is the dominant effect both because this evaluation 
depends on the exact knowledge of the ovulatory period of every woman when taking these 
hormones and because the studies carried on to date have not yet achieved a statistically 
significant number of cases.  
It seems at any rate possible to consider that the discussion about these molecules may be a 
calm scientific debate on its biochemical and clinical aspects. A polemic about the possible 
harmful effects on the embryo does not seem helpful, since the international scientific 
community has already accepted the approach to the safe methods of the intentional abortion. 
This practice is indeed legal, safe and medically supervised in many countries. Finally, it is 
desirable that every woman is enabled to accurately know the effects of every drug at her 
disposal. In so doing she can knowingly choose whether using it or not only depending on her 
conscience and her needs.  
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Tabel 1 
Extract of  “Dedicated Emergency Contraceptive Pills Worldwide” ;  











Albania Norlevo 1,5mg Postinor2   
Algeria Pregnon   
Andorra Norlevo 1,5mg   
Angola Optinor   
Argentina Norgestrel-Max, Norgestrel 
Max unidose 
  
Armenia Escapelle, Postinor   
Australia Levonelle 1*, Norlevo1,5* 
Postinor* 
  
Austria Postinor 1500*, Vikela* ellaOne  
Bahamas Optinor   
Bangladesh Postinor-2   
Belgium Norlevo1,5 *, Postinor*, 
Postinor1500 
  
Bolivia Gianique, ImediatN, 





Optinor   
Botswana Pregnon   
Brazil Diad, Minipil2, Nogravide, 
Pilem,Poslov Postino Uno, 
Postiner, Pozato, Pozato Uni, 
PPMS, Prevyol 
  
Bulgaria Escapelle*, Postinor Duo* ellaOne  
Cambodia Pregnon   
Cameroon Norlevo*, Optinor P2*   




Optinor   
Chile Escapel-1, Escapel-2, 
Optinor, PostDay, Pregnon 
  
China AiWuYu (0,75mg)* AnTing 







 Fu NaiEr(10mg)*, 
HouDingNuo(25mg), HuaDian 
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Denmark Levonelle 1500, Norlevo 1,5 
mg 
ellaOne  
Italy Levonelle, Norlevo 1,5mg, 
Unlevo 1500 
  
Ireland Levonelle 1500, Norlevo 
1,5mg 
  
Lithuania Escapelle*, Postinor* ellaOne  
Luxemburg Norlevo 1,5*, Postinor*, 
Postinor 1,5* 
ellaOne  
Mexico Alterna, Glanique, Ladiades 
0,75, Ladiades 1,5, Postday, 
Postinor-2, Postinor-2 
Unidosis, Silogin 0,75mg, 
Silogin 1,5mg, Vika 
  
Netherland Norlevo 1,5** ,Postinor 
1500** 
  
Norway Norlevo 1,5** Postinor1,5 ** ellaOne  
Portugal Norlevo 1,5*, Postinor 1500* ellaOne  
Russia Escapelle, Escinor 0,75, 
Escinor 1,5 
  
Spain Norlevo 1,5*, Postinor* , 
Postinor 1500* 
  
Sweden Norlevo 1,5*, Postinor 1,5* ellaOne  
Switzerland Norlevo 1,5 mg   
United 
Kingdom 





of America § 
NextChoice*, PlanB*, PlanB 
OneStep 
ella  
* available directly from a pharmacist without a prescription 
** available over the counter 
§ Emergency contraception is available from certain pharmacists without a prescription in 
Alaska, California, Hawaii, M aine, Massachusetts, New Hampshire, New Mexico, 
Washington State, and Vermont. Currently, there are different age restrictions for the EC 
products available in the US. Next Choice and Plan B One-Step are available OTC to women 
and men aged 17 or older. ella is available only 
by prescription to women of any age. 
